Company news
Profusa, Inc. (NASDAQ:PFSA) news
Profusa, Inc. news releases on 6ix. Latest, Sep 15, 2026: Profusa, Inc. Receives Nasdaq Compliance Determination
Press releases & updates
Profusa, Inc. Receives Nasdaq Compliance Determination
September 15, 2026
Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
August 31, 2026
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
August 20, 2026
Profusa Announces 1-for-4 Reverse Stock Split
August 13, 2026
Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
July 31, 2026
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
July 27, 2026
Profusa Announces 1-for-25 Reverse Stock Split
July 1, 2026
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
June 24, 2026
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
June 12, 2026
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
June 10, 2026
Profusa Announces Listing Transfer to The Nasdaq Capital Market
May 15, 2026
Profusa Receives Favorable Nasdaq Listing Determination
May 8, 2026
Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
May 5, 2026
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
April 6, 2026
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
February 27, 2026
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
February 18, 2026
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
February 13, 2026
Profusa Announces 1-for-75 Reverse Stock Split
February 4, 2026
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
January 29, 2026
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
January 15, 2026
Profusa Adds Leading Greek Vascular Surgeon to Customer Base
January 8, 2026
Profusa Bolsters European Commercial Network with New French Distributor, MedSell
December 31, 2025
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35
December 30, 2025
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025
December 15, 2025
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026
December 11, 2025
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
November 24, 2025
Profusa Announces Third Quarter Business and Financial Highlights
November 19, 2025
Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches
October 30, 2025
Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026
October 27, 2025
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
October 21, 2025
Profusa Invests Additional $1 Million in Digital Treasury Assets
October 7, 2025
Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base
October 1, 2025
Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
September 11, 2025
Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base
September 4, 2025
Profusa to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria
August 26, 2025
Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O’Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO
August 18, 2025
Profusa Secures Lumee™ Oxygen Platform Distributor in Spain
July 31, 2025
Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq
July 11, 2025